Cetera Investment Advisers
IOVA icon

Cetera Investment Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Cetera Investment Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Sell
28,235
-2,859
-9% -$10.9K ﹤0.01% 4637
2026
Q1 		$109K Sell
31,094
-39,580
-56% -$127K ﹤0.01% 4428
2025
Q4 		$193K Sell
70,674
-5,348
-7% -$12.4K ﹤0.01% 4247
2025
Q3 		$165K Buy
76,022
+44,208
+139% +$104K ﹤0.01% 4203
2025
Q2 		$54.7K Sell
31,814
-1,794
-5% -$4.46K ﹤0.01% 3965
2025
Q1 		$112K Buy
33,608
+7,814
+30% +$40.3K ﹤0.01% 3753
2024
Q4 		$191K Sell
25,794
-2,797
-10% -$25.9K ﹤0.01% 3438
2024
Q3 		$268K Buy
28,591
+4,255
+17% +$40.3K ﹤0.01% 3166
2024
Q2 		$195K Buy
24,336
+7,310
+43% +$78.3K ﹤0.01% 3368
2024
Q1 		$252K Buy
17,026
+6,564
+63% +$76.4K ﹤0.01% 3184
2023
Q4 		$85.1K Buy
+10,462
New +$54.7K ﹤0.01% 2153

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Cetera Investment Advisers's IOVA Position: Q2 2026 in Review

Cetera Investment Advisers reduced its Iovance Biotherapeutics (IOVA) stake by 9.2% in Q2 2026, selling an estimated $10.9K and leaving 28,235 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #4637.

Cetera Investment Advisers first reported a position in IOVA in Q4 2023 and has held it in 11 quarters since. The position peaked at $268K in Q3 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Cetera Investment Advisers held 28,235 shares of Iovance Biotherapeutics worth $117K as of Q2 2026.
  • Cetera Investment Advisers sold 2,859 Iovance Biotherapeutics shares in Q2 2026, an estimated $10.9K.
  • Iovance Biotherapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #4637 holding.
  • Cetera Investment Advisers first reported a position in Iovance Biotherapeutics in Q4 2023 and has held it in 11 quarters since.
  • Cetera Investment Advisers's Iovance Biotherapeutics position peaked at $268K in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.